ArticleClinical and experimental medicine2025
Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Correspondance: Venetoclax combined with FLAG-based chemotherapy induces rapid and deep responses in early T-cell precursor lymphoblastic leukemia/lymphoma. Report of two cases and review of the literature.Annals of hematology · 2026Article
- Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy.Therapeutic advances in hematology · 2026Review
- Effects of venetoclax, a BCL2 inhibitor, in systemic chronic active Epstein-Barr virus disease.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is a very rare hematological malignancy with a poor prognosis. Conventional cytotoxic regimens have exhibited poor tolerance in clinical practice. Preclinical researches, sparse case reports, and small-scale single-arm studies showed that venetoclax-based salvage chemotherapy had a promising clinical efficacy. However, to date, no case-control studies or prospective trials in relapsed/refractory T-ALL have been conducted to compare venetoclax-based therapies with conventional cytotoxic chemotherapies, owing to the disease's rarity and the challenging treatment landscape. We conducted a retrospective case-cohort study comparing venetoclax-based low-intensity chemotherapy with conventional cytotoxic chemotherapies in the treatment of relapsed/refractory T-ALL. Our results indicated that venetoclax-based chemotherapy achieved comparable outcomes with heavily cytotoxic agents in complete remission rates (58.3% vs. 41.7%, P = 0.759), renal dysfunction (0% vs. 16.7%, P = 0.478), infections (50.0% vs. 75.0%, P = 0.400), and thrombocytopenia duration (17.0 vs. 14.5 days, P = 0.434) between the venetoclax and non-venetoclax cohorts. Additionally, venetoclax-treated patients experienced fewer non-hematological adverse events, such as elevated liver enzymes than conventional cytotoxic chemotherapies (0% vs. 41.6%, P = 0.014), which may be attributed to reduced use of intensive cytotoxic agents like pegylated asparaginase in the venetoclax cohort. Venetoclax-based low-intensity chemotherapy might have a relatively favorable safety profile and non-inferior efficacy compared to conventional cytotoxic regimens. Therefore, venetoclax-based low-intensity chemotherapy might become a potential treatment option, especially for frail patients or those with poor hepatic function who were unable to tolerate multiple cytotoxic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.